Key facts
- This page summarizes Thomas Finnerty's Form 4 filing for Anika Therapeutics, Inc. (ANIK).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Mar 2022, 16:36.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Tax liability
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
Reflects the first vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021.
Footnote F2
Reflects an aggregate of 748 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2022.
Footnote F3
Reflects the closing price of ANIK common stock on March 9, 2022, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
Footnote F4
Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022.